Prognosis
J&J Sees Decision on Vaccine Clearance Coming by March
- Operation Warp Speed officials had seen February availability
- U.S. immunization effort already reeling from slow rollout
A medical worker administers an injection to a volunteer during a phase 3 trial of the Johnson & Johnson Covid-19 vaccine in Barcelona, Spain.
Photographer: Angel Garcia/BloombergThis article is for subscribers only.
Johnson & Johnson’s highly anticipated single-dose Covid-19 vaccine may not be authorized for use until March, weeks later than U.S. officials have suggested.
Operation Warp Speed officials have said they believe that the shot could receive emergency clearance from U.S. regulators as soon as the middle of next month. But that timeline may be aggressive, based on the drugmaker’s expectations for when it will have reliable data in hand demonstrating the one-shot vaccine’s efficacy.